Cargando…

Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers

BACKGROUND: Intensive triplet chemotherapy/bevacizumab significantly increased metastatic colorectal cancer (MCRC) outcome. This phase II study investigated the safety/activity of FIr-C/FOx-C triplet/cetuximab (CET) in first-line RAS wild-type and the prediction of individual limiting toxicity syndr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bruera, Gemma, Massacese, Silvia, Pepe, Francesco, Malapelle, Umberto, Dal Mas, Antonella, Ciacco, Eugenio, Calvisi, Giuseppe, Troncone, Giancarlo, Simmaco, Maurizio, Ricevuto, Enrico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535746/ https://www.ncbi.nlm.nih.gov/pubmed/31205502 http://dx.doi.org/10.1177/1758835919846421

Ejemplares similares

KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy
por: Bruera, Gemma, et al.
Publicado: (2018)

Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: recommended schedule for expected activity and safety and phase II study
por: Bruera, Gemma, et al.
Publicado: (2018)

Dose-finding study of intensive weekly alternating schedule of docetaxel, 5-fluorouracil, and oxaliplatin, FD/FOx regimen, in metastatic gastric cancer
por: Bruera, Gemma, et al.
Publicado: (2018)

Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease
por: Bruera, Gemma, et al.
Publicado: (2012)

Effectiveness and Safety of Intensive Triplet Chemotherapy Plus Bevacizumab, FIr-B/FOx, in Young-Elderly Metastatic Colorectal Cancer Patients
por: Bruera, Gemma, et al.
Publicado: (2013)

Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx)
por: Bruera, Gemma, et al.
Publicado: (2013)

Intensive multidisciplinary treatment strategies and patient resilience to challenge long-term survival in metastatic colorectal cancer: a case report in real life and clinical practice
por: Bruera, Gemma, et al.
Publicado: (2021)

Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype
por: BRUERA, GEMMA, et al.
Publicado: (2013)

Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen
por: BRUERA, GEMMA, et al.
Publicado: (2014)

Pharmacogenomic Assessment of Patients with Colorectal Cancer and Potential Treatments
por: Bruera, Gemma, et al.
Publicado: (2020)

Poorly differentiated neuroendocrine rectal carcinoma with uncommon immune-histochemical features and clinical presentation with a subcutaneous metastasis, treated with first line intensive triplet chemotherapy plus bevacizumab FIr-B/FOx regimen: an experience of multidisciplinary management in clinical practice
por: Bruera, Gemma, et al.
Publicado: (2019)

Relevance of Pharmacogenomics and Multidisciplinary Management in a Young-Elderly Patient With KRAS Mutant Colorectal Cancer Treated With First-Line Aflibercept-Containing Chemotherapy
por: Bruera, Gemma, et al.
Publicado: (2020)

Toxicity Syndromes, Patient-Related Clinical Indicator of Toxicity Burden Induced by Intensive Triplet Chemotherapy-Based Regimens in Gastrointestinal Cancers With Metastatic Disease
por: Bruera, Gemma, et al.
Publicado: (2020)

Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice
por: Cortellini, Alessio, et al.
Publicado: (2019)

"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study
por: Bruera, Gemma, et al.
Publicado: (2010)

FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc
por: Yu, Yiyi, et al.
Publicado: (2016)

Molecular basis of FIR-mediated c-myc transcriptional control
por: Cukier, Cyprian D., et al.
Publicado: (2010)

KRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer
por: Malapelle, U, et al.
Publicado: (2012)

Software tool for training FIR and FIR-OS filters
por: Niittylahti, J, et al.
Publicado: (1993)

[(89)Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer
por: van Helden, E. J., et al.
Publicado: (2019)

C. Fox on Water Analysis
Publicado: (1875)

Pharmacogenomics of hepatitis C infections: personalizing therapy
por: Booth, David R, et al.
Publicado: (2012)

Clinical utility of pharmacogenomics in the management of hepatitis C
por: Trinks, Julieta, et al.
Publicado: (2014)

Reply to: Triplet-triplet annihilation in rubrene/C60 OLEDs with electroluminescence turn-on breaking the thermodynamic limit
por: Engmann, Sebastian, et al.
Publicado: (2019)

Triplet-triplet annihilation effects in rubrene/C(60) OLEDs with electroluminescence turn-on breaking the thermodynamic limit
por: Qiao, Xianfeng, et al.
Publicado: (2019)

Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial
por: Boige, Valérie, et al.
Publicado: (2023)

Localizing triplet periodicity in DNA and cDNA sequences
por: Wang, Liya, et al.
Publicado: (2010)

Generation of Pure State Photon Triplets in the C-Band
por: Su, Xi-Rong, et al.
Publicado: (2019)

C. Fox on Disposal of Slop Water
Publicado: (1875)

The ideal reporting of RAS testing in colorectal adenocarcinoma: a pathologists’ perspective
por: Malapelle, Umberto, et al.
Publicado: (2023)

Dimerization of FIR upon FUSE DNA binding suggests a mechanism of c-myc inhibition
por: Crichlow, Gregg V, et al.
Publicado: (2008)

The life history of the Douglas-fir /
por: Allen, George S.
Publicado: (1972)

Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo
por: Kudo, Kenichiro, et al.
Publicado: (2017)

Biomarkers predictive value in early stage non-small cell lung cancer
por: Malapelle, Umberto, et al.
Publicado: (2020)

Triplet Emitting C^N^C Cyclometalated Dibenzo[c,h]Acridine Pt(II) Complexes
por: Friedel, Joshua, et al.
Publicado: (2022)

Pharmacogenomics of CYP2C9: Functional and Clinical Considerations(†)
por: Daly, Ann K., et al.
Publicado: (2017)

Clinical parameters to guide decision-making in elderly metastatic colorectal cancer patients treated with intensive cytotoxic and anti-angiogenic therapy
por: Bruera, Gemma, et al.
Publicado: (2016)

Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers
por: Chan, Wing-Lok, et al.
Publicado: (2014)

Cetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signature
por: Guo, Sheng, et al.
Publicado: (2016)

Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer
por: Veluchamy, John Pradeep, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_otro35jbfci0slr6fidbuh33bk